Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/5/25 18:33 | 3/3/25 | SWTX | Health | BioPrd | Biological Products, (No Diag | Edris Badreddin | CT | O | COO | 4 | S | -4,331 | 48.12 | 0 | -90 | 230 | D | |||||||||||||||
3/5/25 18:32 | 3/3/25 | SWTX | Health | BioPrd | Biological Products, (No Diag | Islam Saqib | CT | DO | CEO | 6 | S | -11,639 | 49.53 | 0 | -235 | 1,064 | D | |||||||||||||||
2/24/25 18:58 | 2/20/25 | SWTX | Health | BioPrd | Biological Products, (No Diag | Ashar Bhavesh | CT | O | Chief Co | 1 | S | -62 | 61.19 | 0 | -1 | 62 | D | |||||||||||||||
2/24/25 18:57 | 2/20/25 | SWTX | Health | BioPrd | Biological Products, (No Diag | Lynch Daniel | CT | D | 3 | S | -12,421 | 55.70 | 0 | -223 | 131 | D | ||||||||||||||||
2/12/25 20:01 | 2/10/25 | SWTX | Health | BioPrd | Biological Products, (No Diag | Pichl Daniel | CT | O | Chief Pe | 1 | S.d | -1,617 | 54.36 | 0 | -30 | 51 | D | |||||||||||||||
2/12/25 19:57 | 2/10/25 | SWTX | Health | BioPrd | Biological Products, (No Diag | Hambleton Julie | CT | D | 1 | S.d | -730 | 53.01 | 0 | -14 | 4 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |